Type 1 Diabetes

The FDA's decision not to approve sotagliflozin as an adjunct in T1D and CKD comes less than 2 months after a negative advisory committee meeting for the application.

Our Endocrinology Month in Review for November 2024 highlights recent headlines in diabetes and endocrinology as well as 5 new episodes of Diabetes Dialogue.

The 11 to 3 vote against the benefit-risk profile of sotagliflozin comes with less than 2 months to go until the December 20, 2024 PDUFA date.

Our September 2024 monthly recap in endocrinology spotlights regulatory updates, new guidelines, and the latest episodes of Diabetes Dialogue.

The FDA has approved the Eversense 365, the world’s first 1-year continuous glucose monitor, with US availability expected in late 2024.

A follow-up to an earlier episode, this episode features a deep dive into the hosts experience with the Dexcom Stelo sensor.

In this episode, hosts discuss availability of the Abbott Lingo CGM and Embecta’s announcement of FDA clearance for their tubeless patch pump with a 300-unit insulin reservoir.

The endocrinology month in review for August 2024 spotlights 6 pieces of major pipeline news or regulatory announcements as well as multiple episodes of Diabetes Dialogue.

Michigan Medicine and U-M research finds a bidirectional link between mental health disorders and chronic diabetes complications, urging comprehensive screenings.

FDA expands Omnipod 5 AID system for type 2 diabetes, marking the first AID system approved for both type 1 and type 2 diabetes management.

This episode focuses on sotagliflozin in type 1 diabetes and other highlights from the ADCES 2024 annual meeting.

In this episode, hosts react to the announced CMS list prices for the first 10 drugs chosen for negotiation as part of the Inflation Reduction Act.

The first of 2 episodes on ADCES 2024, this episode focuses on sessions and presentations hosts Isaacs and Bellini participated in during the meeting.

In this episode, hosts take a break from the ADCES meeting to discuss the latest news from Medtronic related to their Simplera CGM and their partnership with Abbott.

FDA approval for the Simplera™ continuous glucose monitor marks the company's first disposable, all-in-one CGM half the size of previous offerings.

The July 2024 endocrinology month in review recaps a pair of regulatory updates, multiple studies on incretin therapies, and the most recent episodes of our flagship diabetes podcast, Diabetes Dialogue.

An analysis of more than 11,000 people with T1D found people were more likely to report an affected father than an affected mother.

Results from a Mendelian randomization analysis indicate type 1 diabetes significantly increases the likelihood of autoimmune conditions like rheumatoid arthritis and multiple sclerosis.

The CRL cites requests related to the manufacturing process and the type 1 diabetes indication before the application review can be completed.

In the endocrinology month in review, we spotlight top news in the endocrinology pipeline and the most important updates from ADA 2024.

In this episode, hosts recaps their picks for top diabetes technology-related updates from ADA 2024, including news from Omnipod, MiniMed 780G, and the Tandem mobi.

Carol Levy, MD, discusses INHALE-3 trial and how to incorporate individual patient-level factors into the management of patients with type 1 diabetes who could benefit from inhaled insulin.

Monica Gomberg, MD, joins the podcast to discuss how Blue Circle Health leverages free support and education programs to improve management and quality of life in people with types 1 diabetes.

Davida Kruger, NP, joins the podcast to discuss updates in automated insulin delivery and continuous glucose monitoring systems from ADA 2024.

Findings highlight the potential utility of low-dose SGLT2 inhibitors for optimizing diabetes control and managing renal complications in pediatric patients with type 1 diabetes.

Anastasia Albanese-O'Neill, PhD, APRN, joins Diabetes Dialogue to discuss newly released consensus guidance on monitoring of early-stage type 1 diabetes spearheaded by Breakthrough T1D.

In the special on-site ADA 2024 episode, hosts are joined by the ADA's Chief Scientific and Medical Officer Robert Gabbay, MD, PhD, to discuss the newly formed Obesity Association.

In this episode, hosts are joined by Grazia Aleppo, MD, for a discussion on the use of inhaled insulin following the INHALE-3 trial and relevant updates in diabetes technology at ADA 2024.

Halis Akturk, MD, offers an overview of the growing prevalence and dangers associated with cannabis use among patients with type 1 diabetes.

Use of LX9211 showed significant benefits for diabetic peripheral neuropathic pain in the phase 2 RELIEF-DPN 1 trial.